Conclusions
The severe inflammatory state caused by Sars-CoV-2 infection leads to lung collapse, respiratory difficulties due to fibrosis and death of the patient. The sudden release of cytokines in the circulation, known as ”cytokine storm” (CS), is a phenomenon that must be countered in order not to get scarring of the lung tissue. To date, there are still no effective antivirals that can prevent the evolution of this clinical picture and, pending better solutions, it is good to avoid the patient’s death with the blocking of inflammation and the dissolution of the fibrotic tissue formed. The goal is to save the patient’s life. Correct management of the inflammatory / immune status of the infected patient takes on a priority role. In the third stage, the more serious one, the combined use of anti-inflammatory drugs and pirfenidone can help avoid death from SARS-CoV-2. The use of pirfenidone, for its good tolerability and safety, could be a winning move. In addition, the combined use of multiple drugs allows a safe and non-risky dosage compared to monotherapy and is certainly the most effective and tolerable solution for managing the inflammatory and fibrotic state.
MAIN STATEMENTS
I, the undersigned, Francesco Ferrara and any other author, declare that:
We have no conflict of interest; We have not received funding; There are no sensitive data and no patients were recruited for this study; The document does not conflict with ethical legislation.
Regards
The authors